A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Trial Details

NCT ID
NCT04678648
Phase
PHASE1
Sponsor
RasCal Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • RSC-1255 Dose Escalation
  • RSC-1255 Dose Expansion
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
  • Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
  • Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
  • Malignancy has progressed on standard therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →